Skip to content

Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial

Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a double-blind, randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN27741572
Enrollment
60
Registered
2006-05-09
Start date
2006-03-20
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder (ADHD) Mental and Behavioural Disorders Attention deficit hyperactivity disorder

Interventions

Subjects receiving 6 capsules a day for three months either: 1. 558 mg eicosapentaenoic acid (EPA), 174 mg docosahexaenoic acid (DHA) and 60 mg gamma-linolenic acid (GLA) (per day) 2. 3 g Middle Chain

Sponsors

King's College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Male adolescents aged 12-17 years of age from special schools in London and Kent in the UK 2. Subjects who meet ADHD diagnosis criteria using a structured interview (CHIPS) based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria 3. Subjects who have Conners? Parents ADHD Rating Global Scale and Conners? Teachers ADHD Rating Global Scale above 65

Exclusion criteria

Exclusion criteria: 1. Subjects who took omega-3 supplement within 6 months 2. A personal history of diabetes or other metabolic disorder influencing fatty acid metabolism 3. Subjects who are not living in a family home or residential school 4. Subjects who are under special diets (e.g. vegetarian, taking supplements) 5. Subjects who are not in school during the intervention 6. Serious or chronic disease 7. Low blood coagulation function (e.g. haemophilia, hepatic dysfunction, low-vitamin K) 8. Under these medications: alpha tocopherol, selected anticoagulants (aspirin, warfarin, heparin), cyclosporine, clopidogrel, etretinate and topical steroids, cholesterol-lowering medications (atorvastatin, lovastatin, and simvastatin), non-steroidal anti-inflammatory drugs (NSAIDs), dalteparin, dipyrdamole, enoxaparin, ticlopedine 9. Known allergy for fish product derivatives, Vitamin E derivatives, gelatine 10. Abnormal blood data in the baseline assessment 11. All subjects will score higher than 70 on the prorated IQ as measured by The Kaufman Brief Intelligence Test (K-BIT) 12. For the electroencephalogram (EEG) studies only, subjects with left handed, neurological problems or substance abuse will be excluded

Design outcomes

Primary

MeasureTime frame
Conners? teacher rating scale ADHD index

Secondary

MeasureTime frame
1. Fatty acids deficiency questionnaire 2. 4-Day dietary patterns questionnaire 3. Buss-Perry aggression scale 4. Strength and difficulty questionnaire 5. Depression Anxiety Stress Scales 6. Barratt impulsivity scale 7. Electroencephalography/event-related potential 8. Blood test (phospholipid fatty acids status in red blood cell and plasma) 9. Conners? parent rating scale 10. Neurophysiological measures

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026